Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: The phase II believe study - Murrell, D F; Patsatsi, A; Stavropoulos, P (Br J Dermatol, 2021)
et al.